{
  "docId": "019de075-e341-775b-a82c-decdaeb5c03e",
  "docSlug": "c5ed60c4cc85a094dbae2fa13cb26a34",
  "documentTitle": "Alkermes | Investor Presentation Deck | 37 slides",
  "authorId": "alkermes",
  "authorName": "Mural Oncology",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 37,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 34,
  "notes": "The slide uses a human body diagram to map clinical responses (CR, PR, uPR) by tumor type and treatment regimen.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e341-775b-a82c-decdaeb5c03e/18",
  "deckHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e",
  "deckJsonHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e.json",
  "deckAnchorHref": "/decks/019de075-e341-775b-a82c-decdaeb5c03e#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "image",
      "text": "ARTISTRY-1 (IV Nemvaleukin) Objective Response Summary map",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3830fb6c-0fcb-450a-93d4-85638d3ecc61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "Monotherapy activity (IV) in prior anti-PD-(L)1 treated melanoma and renal cell carcinoma: 10 Objective responses (10 PRs (7 confirmed))",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8944edb8-b8e4-43f0-908b-9e38c35fcfd4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.05,
        "y": 0.5
      },
      "kind": "list",
      "text": "Combination activity (IV) with pembrolizumab in a range of tumor types: 24 Objective responses (5 CRs, 14 PRs, 5uPRs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8d961aa-1701-4cf0-9b07-8a9e6c09b543",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Patients achieved SD (*acral), PR (*RCC), and PD (#RCC) on nemvaleukin monotherapy, rolled over to combination therapy and achieved PR. Data as of March 27, 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9f5b0be7-7ada-4812-89dc-d3d4604357bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ARTISTRY-1: IV Nemvaleukin Demonstrated Durable and Deepening Responses in High Unmet Need Populations",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9e65112-2218-43aa-887a-696ac5fcd888",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "59c25a5c-9ce0-4688-9ac5-7b20dd5595fc",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 12-20 present Nemvaleukin alfa as a solution, including its development approach and clinical results.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}